← 返回

基质 PD-L1 表达在结直肠癌肝转移中的作用

英文原题:Role of stromal PD-L1 expression in colorectal liver metastasis.

查看英文原题

Role of stromal PD-L1 expression in colorectal liver metastasis.

PubMed 2024/01/17(内容时间) BMC Cancer Q2 · IF 4.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

基质 PD-L1 表达可能是 CRLM 的重要预后标志物。

中文摘要

免疫检查点阻断治疗结直肠癌(CRC)的效果不理想,而且对多种癌症肝转移的疗效也较差。本研究探讨结直肠癌肝转移(CRLM)间质程序性死亡配体1(PD-L1)表达与患者预后的关系。

研究纳入84例接受CRC根治性(R0)手术的CRLM患者,并通过免疫组化分析CRLM间质PD-L1表达。

52.3%的CRLM样本表达间质PD-L1;其表达与最佳可切除转移灶较少相关(p=0.04),并有与较低肿瘤分级相关的趋势(p=0.08)。间质PD-L1阳性患者总生存期更长(p=0.003)。多变量分析显示,间质PD-L1表达(p=0.008)和较差分化程度(p<0.001)是独立预后指标。此外,间质PD-L1表达与较高TIL(肿瘤浸润淋巴细胞)数量相关。间质PD-L1阴性且TIL较低组的总生存率低于间质PD-L1阳性且TIL较高组(46.6%比81.8%,p=0.05)。间质PD-L1阳性患者无病生存期(DFS)更长(p=0.03),手术失败时间也更长(p=0.001)。有趣的是,间质PD-L1表达与硬化型组织学生长模式呈正相关(p=0.0002),与替代型模式呈负相关(p=0.008)。

间质PD-L1表达可能是CRLM的重要预后标志物。

展开英文摘要原文

The present study enrolled 84 CRLM patients who underwent surgery (R0) for CRC. Immunohistochemistry was performed to analyze stromal PD-L1 expression in CRLM.

Stromal PD-L1 was expressed in 52.3% of CRLM samples, which was associated with fewer not optimally resectable metastases (p = 0.04). Stromal PD-L1 also tended to associate with a lower tumor grade (p = 0.08). Stromal PD-L1-positive patients had longer overall survival (p = 0.003). Multivariate analysis identified stromal PD-L1 expression (p = 0.008) and poorer differentiation (p < 0.001) as independent prognostic indicators. Furthermore, stromal PD-L1 expression was correlated to a high number of tumor-infiltrating lymphocytes (TILs). Stromal PD-L1- and low TIL groups had shorter OS than stromal PD-L1 + and high TIL groups (46.6% vs. 81.8%, p = 0.05) Stromal PD-L1-positive patients had longer disease-free survival (DFS) (p = 0.03) and time to surgical failure (p = 0.001). Interestingly, stromal PD-L1 expression was positively related to the desmoplastic subtype (p = 0.0002) and inversely related to the replacement subtype of the histological growth pattern (p = 0.008).

Stromal PD-L1 expression may be a significant prognostic marker for CRLM.

论文信息

作者
Takasu C、Morine Y、Yoshikawa K、Nakao T、Tokunaga T、Nishi M、Kashihara H、Wada Y
单位
Department of Surgery, Tokushima University, Tokushima, Japan. takasu.chie@tokushima-u.ac.jp.Japan
期刊
BMC cancer2024 Jan 17
原文标识
PubMed 38233811 · DOI 10.1186/s12885-024-11869-8